Top

Published in:

Open Access 01-12-2014 | Research

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Authors: Karel Decaestecker, Gert De Meerleer, Bieke Lambert, Louke Delrue, Valérie Fonteyne, Tom Claeys, Filip De Vos, Wouter Huysse, Arne Hautekiet, Gaethan Maes, Piet Ost

Published in: Radiation Oncology | Issue 1/2014

Abstract

Purpose

To assess the outcome of prostate cancer (PCa) patients diagnosed with oligometastatic disease at recurrence and treated with stereotactic body radiotherapy (SBRT).

Methods

Non-castrate patients with up to 3 synchronous metastases (bone and/or lymph nodes) diagnosed on positron emission tomography - computed tomography, following biochemical recurrence after local curative treatment, were treated with (repeated) SBRT to a dose of 50 Gy in 10 fractions or 30 Gy in 3 fractions. Androgen deprivation therapy-free survival (ADT-FS) defined as the time interval between the first day of SBRT and the initiation of ADT was the primary endpoint. ADT was initiated if more than 3 metastases were detected during follow-up even when patients were still asymptomatic. Secondary endpoints were local control, progression free survival (PFS) and toxicity. Toxicity was scored using the Common Terminology Criteria for Adverse Events.

Results

With a median follow-up from time of SBRT of 2 years, we treated 50 patients with 70 metastatic lesions with a local control rate of 100%. The primary involved metastatic sites were lymph nodes (54%), bone (44%), and viscera (2%). The median PFS was 19 mo (95% CI: 13–25 mo) with 75% of recurring patients having ≤3 metastases. A 2^nd and 3^rd course of SBRT was delivered in 19 and 6 patients respectively. This results in a median ADT-FS of 25 months (20–30 mo). On univariate analysis, only a short PSA doubling time was a significant predictor for both PFS (HR: 0.90, 95% CI: 0.82 – 0.99) and ADT-FS (HR: 0.83; 95% CI: 0.71 – 0.97). Ten patients (20%) developed toxicity following treatment, which was classified as grade I in 7 and grade II in 3 patients.

Conclusion

Repeated SBRT for oligometastatic prostate cancer postpones palliative androgen deprivation therapy with 2 years without grade III toxicity.

Available only for authorised users

Palmbos PL, Hussain M: Non-castrate metastatic prostate cancer: have the treatment options changed? Semin Oncol 2013, 40: 337-346. 10.1053/j.seminoncol.2013.04.007CrossRefPubMed

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N: EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014, 65: 467-479. 10.1016/j.eururo.2013.11.002CrossRefPubMed

Abrahamsson PA: Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010, 57: 49-59. 10.1016/j.eururo.2009.07.049CrossRefPubMed

Taylor LG, Canfield SE, Du XL: Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115: 2388-2399. 10.1002/cncr.24283CrossRefPubMed

Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES: Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Annals of Oncol 2013, 24: 2881-2886. 10.1093/annonc/mdt335CrossRef

Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G: Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2014, 74: 297-305. 10.1002/pros.22750CrossRefPubMed

Weichselbaum RR, Hellman S: Oligometastases revisited. Nat Rev Clin Oncol 2011, 8: 378-382.PubMed

Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ: Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013, 14: e28-e37. 10.1016/S1470-2045(12)70510-7CrossRefPubMed

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59: 572-583. 10.1016/j.eururo.2011.01.025CrossRefPubMed

10.

Jadvar H: Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011, 52: 81-89. 10.2967/jnumed.110.077941PubMedCentralCrossRefPubMed

11.

De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM: Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 2010, 194: 1427-1433. 10.2214/AJR.10.4263CrossRefPubMed

12.

Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ, European Society of Urogenital R: ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22: 746-757. 10.1007/s00330-011-2377-yPubMedCentralCrossRefPubMed

13.

Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P: Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013, 11: 27-32. 10.1016/j.clgc.2012.08.003CrossRefPubMed

14.

Brown JM, Carlson DJ, Brenner DJ: The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 2014, 88: 254-262. 10.1016/j.ijrobp.2013.07.022PubMedCentralCrossRefPubMed

15.

Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF: Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010, 37: 4078-4101. 10.1118/1.3438081CrossRefPubMed

16.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003,13(3):176-181. 10.1016/S1053-4296(03)00031-6CrossRefPubMed

17.

Yossepowitch O, Bianco FJ Jr, Eggener SE, Eastham JA, Scher HI, Scardino PT: The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007, 51: 940-947. discussion 947–948 10.1016/j.eururo.2006.10.045PubMedCentralCrossRefPubMed

18.

Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P: Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys 2004, 58: 3-10. 10.1016/S0360-3016(03)01442-1CrossRefPubMed

19.

Pasoglou V, Larbi A, Collette L, Annet L, Jamar F, Machiels JP, Michoux N, Berg BC, Tombal B, Lecouvet FE: One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all-in-one” imaging approach? Prostate 2014, 74: 469-477. 10.1002/pros.22764CrossRefPubMed

20.

Richter JA, Rodriguez M, Rioja J, Penuelas I, Marti-Climent J, Garrastachu P, Quincoces G, Zudaire J, Garcia-Velloso MJ: Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010, 12: 210-217. 10.1007/s11307-009-0243-yCrossRefPubMed

21.

Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, Khoder W, Bartenstein P, Stief CG, Loidl W, Seitz M: 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013, 63: 792-796. 10.1016/j.eururo.2012.08.003CrossRefPubMed

22.

Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S: Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011, 97: 49-55.PubMed

23.

Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC, Miralbell R: Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013, 52: 1622-1628. 10.3109/0284186X.2013.764010CrossRefPubMed

24.

Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, Fiorino C, Kirienko M, Incerti E, Messa C, Gianolli L, Di Muzio N: C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014. doi:10.1007/s00259-014-2734-6

25.

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U: Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014, 41: 11-20. 10.1007/s00259-013-2525-5PubMedCentralCrossRefPubMed

26.

Birkhauser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A, Thoeny HC: Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013, 64: 953-960. 10.1016/j.eururo.2013.07.032CrossRefPubMed

27.

Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M: Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 2011,31(4):455-460.CrossRefPubMed

28.

Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR: Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2012, 2: 215.PubMedCentralCrossRefPubMed

29.

Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R: Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82: 889-897. 10.1016/j.ijrobp.2010.11.031CrossRefPubMed

30.

Pai HH, Pickles T, Keyes M, Jones S, McDonald RE, Lesperance M, Berthelet E: Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists. Can Urol Assoc J 2011, 5: 173-179. 10.5489/cuaj.10102PubMedCentralCrossRefPubMed

Title: Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence
Authors: Karel Decaestecker
Gert De Meerleer
Bieke Lambert
Louke Delrue
Valérie Fonteyne
Tom Claeys
Filip De Vos
Wouter Huysse
Arne Hautekiet
Gaethan Maes
Piet Ost
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-9-135

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy

Updates on clinical studies of selenium supplementation in radiotherapy

Dual-gated volumetric modulated arc therapy

Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation

Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience

The sensitivity of gamma-index method to the positioning errors of high-definition MLC in patient-specific VMAT QA for SBRT